---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-026338"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T18:08:36.700128+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel acquires U.S. rights to Blueprint's pralsetinib for $15M plus milestones

## Summary
- Purchase price $15M: $10M at first commercial sale, $5M one year after closing.
- Up to $97.5M in commercial milestones and $5M in regulatory milestones.
- Blueprint receives tiered royalties of 10-30% on net sales of pralsetinib products.
- Pralsetinib is an approved RET inhibitor for metastatic NSCLC and advanced thyroid cancer.
- Rigel expects to recognize product sales starting in Q3 2024 using its commercial infrastructure.

## SEC filing metadata
- accession: 0001104659-24-026338
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924026338/0001104659-24-026338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924026338/tm246898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-026338
- JSON: https://secwatch.observer/filing/0001104659-24-026338.json
- Plain text: https://secwatch.observer/filing/0001104659-24-026338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.